SPIOMET4HEALTH is an EU-funded health project whose main objective is to study, in a multi-centric phase II clinical trial, a new treatment for Polycystic Ovary Syndrome (PCOS) in adolescent girls and young adult women.
The initiative, funded by the European Commission with a budget of 6 million euros, has recently kicked off and will last 5 years. The SPIOMET4HEALTH is part of the Horizon Europe Programme health projects, and this specific project aims at improving the quality of life of PCOS patients.
What is Polycystic Ovary Syndrome (PCOS)?
The Polycystic Ovary Syndrome the most common endocrine-metabolic disorder among women of reproductive age, affecting 5-10% of women worldwide.
This syndrome is the most frequent cause of anovulatory subfertility, and it is also associated with other lifelong disorders like type 2 diabetes, premenopausal cancer and anxiety/depression, with a negative impact on the health and quality of life of these subjects and their offspring.
Currently there are no approved treatments to improve and resolve Polycystic Ovary Syndrome (PCOS) in young people or adults. Most of them receive medical indications that alleviate the symptoms but do not reverse the pathology.
The contribution of SPIOMET4HEALTH to the quality of life of PCOS patients
SPIOMET4HEALTH proposes as a treatment for PCOS a single SPIOMET tablet composed of spironolactone (SPI) 50mg; pioglitazone (PIO) 7.5 mg; and metformin (MET) 850 mg).
Thanks to the SPIOMET4HEALTH project, it will be possible to test the efficacy of the new treatment for PCOS.
Partners in the challenge of SPIOMET4HEALTH
This PCOS project has 17 partner organisations which are coordinated by the Fundació Sant Joan de Déu/Hospital Sant Joan de Déu. At ASPHALION we are proud Regulatory Partners of this European granted project. We are also more than happy to share a press release about it.
If you need further information or would like to discuss a collaboration, you can contact us at: [email protected]
